Sign In
Buy MSOS
$4.74
-0.310 (-6.14%)
At Close: Jun 03, 2026
MSOS: Cannabis Investors Should Be Careful With This ETF
09:05am, Thursday, 23'rd Apr 2026
AdvisorShares Pure US Cannabis ETF remains a Strong Sell due to extreme concentration in three names and excessive volatility. Potential cannabis rescheduling could eliminate 280E taxation, boosting n
MSOS: Trump's Green Light - Why Cannabis Stocks Are Surging On Rescheduling News (Rating Upgrade)
04:19pm, Wednesday, 22'nd Apr 2026
I am upgrading the AdvisorShares Pure US Cannabis ETF to a buy rating due to imminent regulatory catalysts. Potential cannabis rescheduling to Schedule III would eliminate 280e taxes, materially boost
NLCP And MSOS: Cannabis REIT Vs. ETF
07:54pm, Thursday, 09'th Apr 2026
NewLake Capital Partners, Inc. (NLCP) offers defensiveness and a 12% dividend yield, outperforming MSOS over the past three years. MSOS, an ETF heavily concentrated in top cannabis stocks, remains exp
MSOS: The Question Is Not If, But 'When' The Rescheduling Will Occur
02:36pm, Thursday, 12'th Mar 2026
I reiterate a Buy rating on AdvisorShares Pure US Cannabis ETF, emphasizing its compelling risk-return profile despite recent volatility. MSOS trades at 1.7x sales, below its historical average of 2x,
The One IRS Rule Keeping Cannabis Stocks Down Despite Record Cash Flow
10:16am, Thursday, 12'th Mar 2026
Retail investors in r/options are making an unusual bet on AdvisorShares Pure US Cannabis ETF ( NYSEARCA:MSOS ), and the activity is hard to ignore.
Investors Purchase Large Volume of Call Options on AdvisorShares Pure US Cannabis ETF (NYSEARCA:MSOS)
01:11am, Tuesday, 24'th Feb 2026
AdvisorShares Pure US Cannabis ETF (NYSEARCA:MSOS - Get Free Report) was the recipient of unusually large options trading activity on Monday. Traders purchased 75,622 call options on the company. This
3 Reasons Why These 3 Cannabis Stocks Could Have a Magnificent 2026
08:45am, Tuesday, 27'th Jan 2026
The cannabis sector is one which many may have rightly described as a bubble seven or eight years ago.
Trump's Cannabis Rescheduling Order Could Finally Kill A Crushing Tax Rule And Transform US Weed Stocks, Says Expert
08:16am, Monday, 19'th Jan 2026
Dan Ahrens analyzes Trump's historic cannabis shift. Learn how Schedule 3 could end the 280E "narcotics trafficker" tax for US pot stocks.
Santa Rally Falls Short: Top ETF Performers of December
09:00am, Friday, 02'nd Jan 2026
Santa Rally fizzled as markets stumbled, but ETFs tied to cannabis (MSOS, WEED), metals (SLV, PPLT) and space (UFO) surged.
2 Marijuana Stocks To Watch For Better Investing In 2026
01:05pm, Sunday, 28'th Dec 2025
The cannabis industry continues evolving into a bigger and more regulated global market. Legalization trends are expanding across the United States and international regions. This growth fuels long-te
3 Marijuana Stocks To Watch In 2026
01:58pm, Friday, 26'th Dec 2025
The cannabis industry is entering another critical growth phase, positioning 2026 as a potentially pivotal year. Particularly for long-term investors looking to make a profit with marijuana stocks. Af
Marijuana Stocks To Watch After The Holidays
11:52am, Wednesday, 24'th Dec 2025
In 2026, the impact of cannabis rescheduling is expected to be far more visible in marijuana stock performance. Much more than in the initial announcement of cannabis becoming a Class 3 substance. Whi
3 Top Marijuana Stocks After Cannabis Gets Rescheduled
11:35am, Monday, 22'nd Dec 2025
Donald Trump's recent executive order moving cannabis off Schedule I marks a pivotal moment for the U.S. cannabis sector. While the order does not legalize marijuana at the federal level, rescheduling
Benzinga Bulls And Bears: Carnival, Caterpillar, Meta — And Markets Make Modest Gains
08:31am, Saturday, 20'th Dec 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week - here's a look at some of our top stories.
3 Best Cannabis Stocks: Will They Fly High Again Post Trump Schedule III?
06:52pm, Friday, 19'th Dec 2025
Cannabis stocks sold off this week following President Trump's Executive Order directing marijuana's reclassification to Schedule III for increased medical and cannabidiol research. The sharp selloff
